Trial Results for New Lung Cancer Drug Are “Off the Charts”
“More than half of patients (60%) diagnosed with advanced forms of lung
cancer who took lorlatinib were still alive five years later with no
progression in their disease, data presented at the world’s largest
cancer conference showed. The rate was 8% in patients treated with a
standard drug, the trial found. The results are the […]
The post Trial Results for New Lung Cancer Drug Are “Off the Charts”
appeared first on Human Progress.
https://humanprogress.org/trial-results-for-new-lung-cancer-drug-are-off-the-charts/View article
View summary